Pyxis Oncology, Inc.

Informe acción NasdaqGS:PYXS

Capitalización de mercado: US$112.8m

Pyxis Oncology Dirección

Dirección controles de criterios 3/4

El CEO de Pyxis Oncology es Tom Civik, nombrado en Feb 2026, tiene una permanencia de menos de un año. posee directamente un 0.35% de las acciones de la empresa, con un valor de $394.95K. La antigüedad media del equipo directivo y de la junta directiva es de 1.2 años y 4.7 años, respectivamente.

Información clave

Tom Civik

Chief Executive Officer (CEO)

US$75.9k

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEOless than a year
Participación del CEO0.4%
Permanencia media de la dirección1.2yrs
Promedio de permanencia en la Junta Directiva4.7yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • Sep 12

Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade)

Summary PYXS is developing micvotabart pelidotin for head and neck squamous cell carcinoma, with key clinical readouts expected in H2'25 and H1'26. While micvotabart pelidotin has shown early efficacy and tolerability, limited patient data and competition raise concerns. PYXS has cash runway into H2'26 but faces risk from potential clinical disappointments, competitor updates, and possible dilutive fundraising. Read the full article on Seeking Alpha
Artículo de análisis • Jun 19

Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Dec 07

Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead

Summary Pyxis Oncology's lead candidate, PYX-201, showed promising response rates in Phase 1 trials but raised safety concerns due to a patient's death. The company’s valuation appears deeply discounted, with a P/B ratio of 0.7 compared to a sector median of 2.4, reflecting market pessimism. PYX-201's ongoing trials and upcoming catalysts in 2025-2026 are crucial for addressing safety concerns and demonstrating efficacy across multiple cancer types. Investors should consider PYXS's financial runway, speculative nature, and potential for significant stock appreciation if future trial results are favorable. Despite setbacks, PYXS's valuation appears deeply oversold, presenting a speculative "Buy" opportunity due to its robust pipeline and potential revenue from licensing. Read the full article on Seeking Alpha
Seeking Alpha • Sep 13

Moment Of Truth Approaches For Pyxis Oncology

Summary Pyxis Oncology is an antibody and antibody-drug conjugate developer with initial results from two clinical trials ahead in 2024. Data from a phase 1 study of PYX-201, an ADC targeting extra domain B of fibronectin, in multiple tumor types, are expected in fall 2024. Data from a phase 1 study of PYX-106, an anti-Siglec-15 antibody, in multiple tumor types, are expected by year-end 2024. PYXS estimates its current cash will last until H2'26. Read the full article on Seeking Alpha
Seeking Alpha • Jun 10

Pyxis Oncology: Promising Research Amid Cash Constraints

Summary Pyxis Oncology develops innovative therapeutics for hard-to-treat cancers using antibody-drug conjugates and immunotherapies. The company's pipeline includes PYX-201 and PYX-106, targeting multiple solid tumor types, with preliminary data expected in 2024. Pyxis recently announced a workforce reduction and sold the royalties and commercialization rights of Beovu to extend its cash runway. Despite innovative technology, PYXS faces financial constraints and early-stage development risks. A neutral stance on PYXS is prudent due to speculative IP and potential shareholder dilution. Read the full article on Seeking Alpha
Seeking Alpha • Mar 28

Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait

Summary Pyxis Oncology is developing antibodies and antibody-drug conjugates for various tumor types. Initial data from the phase 1 trials of PYX-106 and PYX-201 are now expected in H2'24 and fall 2024 respectively. PYXS raised $50M in gross proceeds with a private placement in February 2024 and is cashed into H2'26. Read the full article on Seeking Alpha
Seeking Alpha • Jan 18

Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis

Summary Pyxis Oncology is a biotech company focused on developing immunotherapies for cancer treatment. Their most advanced pipeline project is sotigalimab, a CD40 agonist, which has shown promising results in melanoma and liposarcoma. The company has enough funds to continue operating for 5-6 quarters, but future funding may require dilutive financing. Read the full article on Seeking Alpha
Artículo de análisis • Feb 18

Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Artículo de análisis • Sep 01

Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 15

Pyxis Oncology GAAP EPS of -$0.79 beats by $0.06

Pyxis Oncology press release (NASDAQ:PYXS): Q2 GAAP EPS of -$0.79 beats by $0.06. Pyxis Oncology had cash and cash equivalents of $223 million as of June 30, 2022, and approximately $207 million (preliminary, unaudited) as of August 15, 2022, which is expected to fund operations through the second half of 2024.
Artículo de análisis • Apr 13

We're Hopeful That Pyxis Oncology (NASDAQ:PYXS) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

CEO

Tom Civik (56 yo)

less than a year
Permanencia
US$75,904
Compensación

Mr. Thomas Civik, also known as Tom, is Independent Chairman of the Board at ImCheck Therapeutics SAS since March 2023. He is Interim CEO & Director of Pyxis Oncology, Inc. from February 3, 2026. He was In...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Thomas Civik
Interim CEO & Directorless than a yearUS$75.90k0.35%
$ 395.0k
Jitendra Wadhane
Chief Accounting Officer4.8yrsUS$766.75k0.51%
$ 573.2k
Balu Balasubramanian
Interim Chief Technology Officer4.3yrssin datossin datos
Alex Kane
Senior Vice President of Investor Relations & Capital Marketsless than a yearsin datossin datos
Donna Regalado
Head of Human Resources1.3yrssin datossin datos
Charles Gombar
Senior Vice President of Portfolio & Program Management4.3yrssin datossin datos
Michael Bui
Senior Vice President of Global Regulatory Affairs1.2yrssin datossin datos
Supriya Roth
Head of Commercial Development1.2yrssin datossin datos
Shui He
Head of Biometrics1.2yrssin datossin datos
Hongwei Wang
Head of ADC Development & Clinical Strategy1.2yrssin datossin datos
Marsha Crochiere
Head of Translational Medicine & Research1.2yrssin datossin datos
Chris Cohen
Head of Drug Safety & Pharmacovigilance1.3yrssin datossin datos
1.2yrs
Permanencia media

Equipo directivo experimentado: El equipo directivo de PYXS no se considera experimentado ( 1.2 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Thomas Civik
Interim CEO & Director4.7yrsUS$75.90k0.35%
$ 395.0k
John Flavin
Independent Chairman7yrsUS$155.90k0.65%
$ 735.2k
Anthony Tolcher
Member of Clinical & Translational Medicine Advisory Board4.9yrssin datossin datos
Freda Lewis-Hall
Independent Director4.7yrsUS$73.40k0.38%
$ 429.7k
Darren Cline
Independent Director4.7yrsUS$83.40k0.40%
$ 447.5k
Santhosh Palani
Independent Director2.2yrsUS$127.78k0%
$ 0
Jason J. Luke
Member of Clinical & Translational Medicine Advisory Boardno datasin datossin datos
Christopher O'Donnell
Member of Technical Advisory Board4.1yrssin datossin datos
Morris Rosenberg
Chairperson of Technical Advisory Boardno datasin datossin datos
Robert Baffi
Member of Technical Advisory Boardno datasin datossin datos
Virgil Lawlis
Member of Technical Advisory Boardno datasin datossin datos
Michael Sun
Member of Technical Advisory Boardno datasin datossin datos
4.7yrs
Permanencia media
55.5yo
Promedio de edad

Junta con experiencia: La junta directiva de PYXS se considera experimentada (4.7 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/29 23:19
Precio de las acciones al final del día2026/05/29 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Pyxis Oncology, Inc. está cubierta por 13 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Tazeen AhmadBofA Global Research
Bradley CaninoGuggenheim Securities, LLC
Swayampakula RamakanthH.C. Wainwright & Co.